111 related articles for article (PubMed ID: 12520188)
21. Hydroxycamptothecin nanoparticles based on poly/oligo (ethylene glycol): Architecture effects of nanocarriers on antitumor efficacy.
Guo Y; Wang T; Qiu H; Han M; Dong Z; Wang X; Wang Y
Eur J Pharm Biopharm; 2019 Jan; 134():178-184. PubMed ID: 30529294
[TBL] [Abstract][Full Text] [Related]
22. Green synthesis of methoxy-poly(ethylene glycol)-block-poly(l-lactide-co-glycolide) copolymer using zinc proline as a biocompatible initiator for irinotecan delivery to colon cancer in vivo.
Giram PS; Wang JT; Walters AA; Rade PP; Akhtar M; Han S; Faruqu FN; Abdel-Bar HM; Garnaik B; Al-Jamal KT
Biomater Sci; 2021 Feb; 9(3):795-806. PubMed ID: 33206082
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and antitumor efficacy of chemoembolization using 40 µm irinotecan-loaded microspheres in a rabbit liver tumor model.
Tanaka T; Nishiofuku H; Hukuoka Y; Sato T; Masada T; Takano M; Gilbert CW; Obayashi C; Kichikawa K
J Vasc Interv Radiol; 2014 Jul; 25(7):1037-1044.e2. PubMed ID: 24861663
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].
Yang FY; Zhang WP; Chen HL; Fu Y; Wang XY; Wei SJ; Yang XY; Zhang YX; Dang HW
Yao Xue Xue Bao; 2013 Jun; 48(6):940-5. PubMed ID: 23984532
[TBL] [Abstract][Full Text] [Related]
25. [The preparation of PELGE-NP and a study of the factors affecting their diameter].
Duan YR; Zhang ZR; Tang YG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jan; 36(1):115-8. PubMed ID: 15702798
[TBL] [Abstract][Full Text] [Related]
26. Enzyme sensitive, surface engineered nanoparticles for enhanced delivery of camptothecin.
Yu H; Chen J; Liu S; Lu Q; He J; Zhou Z; Hu Y
J Control Release; 2015 Oct; 216():111-20. PubMed ID: 26282096
[TBL] [Abstract][Full Text] [Related]
27. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
[TBL] [Abstract][Full Text] [Related]
28. Development of a novel biocompatible poly(ethylene glycol)-block-poly(γ-cholesterol-L-glutamate) as hydrophobic drug carrier.
Ma Q; Li B; Yu Y; Zhang Y; Wu Y; Ren W; Zheng Y; He J; Xie Y; Song X; He G
Int J Pharm; 2013 Mar; 445(1-2):88-92. PubMed ID: 23376505
[TBL] [Abstract][Full Text] [Related]
29. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38.
Ebrahimnejad P; Dinarvand R; Sajadi SA; Atyabi F; Ramezani F; Jaafari MR
PDA J Pharm Sci Technol; 2009; 63(6):512-20. PubMed ID: 20169857
[TBL] [Abstract][Full Text] [Related]
31. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation.
Xin H; Chen L; Gu J; Ren X; Wei Z; Luo J; Chen Y; Jiang X; Sha X; Fang X
Int J Pharm; 2010 Dec; 402(1-2):238-47. PubMed ID: 20934500
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable thermo-sensitive nanoparticles from poly(L-lactic acid)/poly(ethylene glycol) alternating multi-block copolymer for potential anti-cancer drug carrier.
Na K; Lee KH; Lee DH; Bae YH
Eur J Pharm Sci; 2006 Feb; 27(2-3):115-22. PubMed ID: 16253487
[TBL] [Abstract][Full Text] [Related]
34. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
35. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.
Williams J; Lansdown R; Sweitzer R; Romanowski M; LaBell R; Ramaswami R; Unger E
J Control Release; 2003 Aug; 91(1-2):167-72. PubMed ID: 12932648
[TBL] [Abstract][Full Text] [Related]
36. Poly(ethylene glycol) shell-sheddable nanomicelle prodrug of camptothecin with enhanced cellular uptake.
Wu Q; Du F; Luo Y; Lu W; Huang J; Yu J; Liu S
Colloids Surf B Biointerfaces; 2013 May; 105():294-302. PubMed ID: 23384692
[TBL] [Abstract][Full Text] [Related]
37. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice.
Zhang L; Yang M; Wang Q; Li Y; Guo R; Jiang X; Yang C; Liu B
J Control Release; 2007 Jun; 119(2):153-62. PubMed ID: 17400320
[TBL] [Abstract][Full Text] [Related]
38. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.
Jiang X; Xin H; Sha X; Gu J; Jiang Y; Law K; Chen Y; Chen L; Wang X; Fang X
Int J Pharm; 2011 Nov; 420(2):385-94. PubMed ID: 21920419
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
40. [Preparation and degradation behavior of PELGE nanoparticles].
Duan Y; Zhang Z; Tang Y; Lin Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):921-5. PubMed ID: 15646333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
